Eagle Health Investments LP Takes Position in Ascendis Pharma A/S $ASND

Eagle Health Investments LP purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) during the first quarter, Holdings Channel.com reports. The institutional investor purchased 86,650 shares of the biotechnology company’s stock, valued at approximately $19,819,000. Ascendis Pharma A/S comprises about 3.5% of Eagle Health Investments LP’s portfolio, making the stock its 11th largest position.

Several other large investors have also recently made changes to their positions in the company. Advisory Services Network LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at $26,000. Arax Advisory Partners boosted its stake in Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 104 shares during the last quarter. Leonteq Securities AG acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $42,000. Finally, Global Retirement Partners LLC grew its holdings in shares of Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after buying an additional 113 shares in the last quarter.

Analyst Ratings Changes

ASND has been the topic of several research reports. Bank of America raised their price target on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Wedbush reaffirmed an “outperform” rating and set a $273.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. Morgan Stanley increased their price objective on shares of Ascendis Pharma A/S from $256.00 to $275.00 and gave the company an “overweight” rating in a report on Thursday. Wells Fargo & Company decreased their target price on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Royal Bank Of Canada boosted their target price on Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $296.72.

Ascendis Pharma A/S Stock Down 0.2%

Shares of ASND opened at $253.42 on Tuesday. Ascendis Pharma A/S has a 52-week low of $160.86 and a 52-week high of $282.15. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The stock has a fifty day simple moving average of $244.40 and a two-hundred day simple moving average of $233.91. The company has a market capitalization of $15.81 billion, a PE ratio of 29.23 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to analyst estimates of $362.47 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post 4.49 EPS for the current year.

Insider Activity

In other news, Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, May 26th. The shares were bought at an average cost of $237.80 per share, with a total value of $95,120.00. Following the completion of the purchase, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by company insiders.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.